Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EDIT Editas Medicine	$2.75 -3.5%	$2.03	$0.91 ▼ $6.05	$238.58M	2.15	2.64 million shs	1.55 million shs
INMB INmune Bio	$2.07 -2.4%	$6.12	$1.89 ▼ $11.64	$50M	1.34	827,877 shs	1.41 million shs
MDWD MediWound	$20.01 -2.2%	$20.10	$14.14 ▼ $22.51	$221.23M	0.32	65,822 shs	61,788 shs
SLS SELLAS Life Sciences Group	$1.90 -4.0%	$1.77	$0.77 ▼ $2.27	$197.56M	2.31	1.82 million shs	10.76 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EDIT Editas Medicine	-3.51%	-3.85%	+39.59%	+116.54%	-50.98%
INMB INmune Bio	-2.36%	-10.00%	-73.12%	-71.68%	-78.28%
MDWD MediWound	-2.25%	+3.25%	-2.01%	+22.84%	-1.96%
SLS SELLAS Life Sciences Group	-4.04%	-9.09%	+14.46%	+48.44%	+74.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EDIT Editas Medicine	4.2042 of 5 stars	3.2	2.0	4.3	3.7	2.5	0.6
INMB INmune Bio	2.3066 of 5 stars	3.3	1.0	0.0	3.8	1.7	0.6
MDWD MediWound	1.6119 of 5 stars	3.5	1.0	0.0	1.6	0.8	0.6
SLS SELLAS Life Sciences Group	0.3595 of 5 stars	0.0	1.0	0.0	2.2	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EDIT Editas Medicine	2.31	Hold	$4.70	70.91% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	788.89% Upside
MDWD MediWound	3.00	Buy	$32.25	61.17% Upside
SLS SELLAS Life Sciences Group	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INMB, SLS, EDIT, and MDWD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
4/29/2025	EDIT Editas Medicine	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.00
4/28/2025	EDIT Editas Medicine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EDIT Editas Medicine	$35.84M	6.42	N/A	N/A	$1.63 per share	1.69
INMB INmune Bio	$10K	4,881.06	N/A	N/A	$1.45 per share	1.43
MDWD MediWound	$20.22M	10.70	N/A	N/A	$2.89 per share	6.92
SLS SELLAS Life Sciences Group	$1M	189.58	N/A	N/A	$0.13 per share	14.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$1.93	N/A	N/A	N/A	N/A	-119.35%	-89.37%	7/30/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/13/2025 (Estimated)
SLS SELLAS Life Sciences Group	-$30.88M	-$0.38	N/A	N/A	N/A	N/A	-193.67%	-113.02%	8/12/2025 (Estimated)

Latest INMB, SLS, EDIT, and MDWD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	N/A	MDWD MediWound	-$0.55	N/A	N/A	N/A	$5.68 million	N/A
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	EDIT Editas Medicine	-$0.40	N/A	N/A	N/A	$1.81 million	N/A
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/13/2025	Q1 2025	SLS SELLAS Life Sciences Group	-$0.1067	-$0.07	+$0.0367	-$0.07	N/A	N/A
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EDIT Editas Medicine	N/A	3.08	3.08
INMB INmune Bio	N/A	2.64	2.64
MDWD MediWound	N/A	2.15	1.99
SLS SELLAS Life Sciences Group	N/A	4.64	4.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EDIT Editas Medicine	71.90%
INMB INmune Bio	12.72%
MDWD MediWound	46.83%
SLS SELLAS Life Sciences Group	17.38%

Insider Ownership

Company	Insider Ownership
EDIT Editas Medicine	1.90%
INMB INmune Bio	35.70%
MDWD MediWound	9.20%
SLS SELLAS Life Sciences Group	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EDIT Editas Medicine	230	83.71 million	82.12 million	Optionable
INMB INmune Bio	10	23.58 million	15.17 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable
SLS SELLAS Life Sciences Group	10	99.78 million	98.58 million	Not Optionable

INMB, SLS, EDIT, and MDWD Headlines

Recent News About These Companies

SELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - Nasdaq

July 9, 2025 | nasdaq.com

SELLAS Life Sciences Group (NASDAQ:SLS) Stock Price Down 3.7% - Here's What Happened

July 9, 2025 | marketbeat.com

Sellas Life Sciences appoints Linghua Wang to Scientific Advisory Board

July 7, 2025 | msn.com

SELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory Board

July 7, 2025 | globenewswire.com

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Galena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock?

June 23, 2025 | zacks.com

Sellas Life Sciences: Tons Of Completed Studies

June 17, 2025 | seekingalpha.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Increase in Short Interest

June 16, 2025 | marketbeat.com

Nostrand Robert L. Van Purchases 10,000 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Stock

June 14, 2025 | insidertrades.com

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

June 5, 2025 | globenewswire.com

SELLAS Life Sciences Presents Preclinical Data on SLS009 as a Targeted Therapy for ASXL1 Mutated Colorectal Cancer at ASCO 2025

June 4, 2025 | nasdaq.com

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Director Jane Wasman Buys 20,000 Shares

June 3, 2025 | insidertrades.com

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

June 2, 2025 | globenewswire.com

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

May 20, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Common Stock

May 16, 2025 | fxempire.comF

Sellas doses first paediatric subject with AML in Phase II trial of SLS009

May 16, 2025 | msn.com

SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | finanznachrichten.de

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

May 15, 2025 | globenewswire.com

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025 | globenewswire.com

SELLAS Life Sciences Group, Inc. Presents Promising Preclinical Data on SLS009 for TP53 Mutated Acute Myeloid Leukemia at AACR 2025

April 28, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
EV Tax Credits Are Ending—Here’s Why These 2 Stocks Could Soar
By Leo Miller | July 8, 2025
View EV Tax Credits Are Ending—Here’s Why These 2 Stocks Could Soar
Capitalize on Volatility: 3 Finance Stocks Thriving in 2025
By Chris Markoch | July 2, 2025
View Capitalize on Volatility: 3 Finance Stocks Thriving in 2025

INMB, SLS, EDIT, and MDWD Company Descriptions

Editas Medicine NASDAQ:EDIT

$2.75 -0.10 (-3.51%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$2.73 -0.02 (-0.73%)

As of 07/15/2025 07:59 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

INmune Bio NASDAQ:INMB

$2.07 -0.05 (-2.36%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.02 (+0.72%)

As of 07/15/2025 07:50 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

MediWound NASDAQ:MDWD

$20.01 -0.46 (-2.25%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$20.07 +0.05 (+0.27%)

As of 07/15/2025 04:04 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

SELLAS Life Sciences Group NASDAQ:SLS

$1.90 -0.08 (-4.04%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$1.88 -0.01 (-0.79%)

As of 07/15/2025 07:59 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time